Skip to main content

Table 2 Number of completed trials registered on ClinicalTrials.gov, of which results have been published on ClinicalTrials.gov or in the academic literature. Percentages are displayed as a proportion of all completed trials

From: Missing clinical trial data: the evidence gap in primary data for potential COVID-19 drugs

Generic name Completed Results on NCT Academic publication only Results unreported
Pirfenidone 54 18 (33.3%) 20 (37.0%) 16 (29.6%)
Hydroxychloroquine 154 38 (24.7%) 59 (38.3%) 57 (37.0%)
Azithromycin 343 78 (22.7%) 119 (34.7%) 146 (42.6%)
Favipiravir 9 1 (11.1%) 1 (11.1%) 7 (77.8%)
Oseltamivir 101 38 (37.6%) 18 (17.8%) 45 (44.6%)
Sarilumab 18 13 (72.2%) 2 (11.1%) 3 (16.7%)
Tocilizumab (atlizumab) 267 125 (46.8%) 44 (16.5%) 98 (36.7%)
Remdesivir 1 0 (0.0%) 0 (0.0%) 1 (100%)
Leflunomide 20 5 (25.0%) 4 (20.0%) 11 (55.0%)
Interferon-alpha 1049 347 (33.1%) 301 (28.7%) 401 (38.2%)
Lopinavir/ritonavir 927 287 (31.0%) 265 (28.6%) 375 (40.5%)
Darunavir/ritonavir 216 73 (33.8%) 66 (30.6%) 77 (35.6%)
Baloxavir marboxil 5 2 (40.0%) 0 (0.0%) 3 (60.0%)
Umifenovir 2 0 (0.0%) 2 (100.0%) 0 (0.0%)
Interferon-beta 285 84 (29.5%) 84 (29.5%) 117 (41.1)
Sofosbuvir 176 36 (20.5%) 42 (23.9%) 98 (55.7%)
Nitazoxanide 48 11 (22.9%) 12 (25.0%) 25 (52.1%)
APN01 (ACE2 analogue) 1 0 (0.0%) 1 (100.0%) 0 (0.0%)
Ivermectin 78 16 (20.5%) 26 (33.3%) 36 (46.2%)
Totals 3754 1172 (31.2%) 1066 (28.4%) 1516 (40.4%)